Dr Florence Camus-Bablon discusses strategies to facilitate the uptake of quality paediatric antimalarials.
In 2011, 610 000 to 971 000 lives were lost to malaria, mainly in Africa; 86% of them children under 5 years old.1 Malaria accounts for 24% of total child deaths in sub-Saharan Africa.1 The continent is losing a child every minute to this disease.
This tragic loss occurs in spite of the availability of new paediatric ACTs in accordance with World Health Organization (WHO) guidelines. To better understand the reasons behind this apparent lack of uptake, Medicines for Malaria Venture (MMV) commissioned a study released in 2012 to identify barriers to the use of WHO-recommended paediatric medicines. The results of the study brought a number of important issues to light.
In this article available on the Africa Health website, Dr Florence Camus-Bablon discusses strategies to facilitate the uptake of quality paediatric antimalarials.